Sepsis is as difficult a problem today as it was in the sixteenth century when Niccolo Machiavelli wrote "the physicians say it happens in hectic fever, that in the beginning of the malady it is easy to cure but difficult to detect, but in the course of time, not having been either detected or treated in the beginning, it becomes easy to detect but difficult to cure." Early drainage or excision of the infected site and antimicrobial therapy are key components of effective sepsis therapy. Appropriate fluid resuscitation and maintenance of adequate haemodynamics with vasopressors and inotropes are also indicated and recommended in the Surviving Sepsis Guidelines 1 . Gordon et al. recently published the negative findings of their prospective double-blinded, randomized control trial that investigated the efficacy of levosimendan in 516 patients with septic shock 2 . Levosimendan is a calcium sensitizer with inotropic and vasodilator properties. This drug is approved for the treatment of heart failure in many countries (not including the USA). In the recent trial, patients with septic shock received a 24 h infusion of either levosimendan or placebo in addition to standard care. Additional inotropic support (dobutamine) could also be added at the clinician's discretion. The effects of levosimendan therapy likely persisted for approximately 1 week owing to the long half-life of its active metabolite.
prominent is an increase in oxygen delivery owing to its inotropic and afterload-reducing properties. Thus, if impaired oxygen delivery underlies organ failure in patients with sepsis, levosimendan treatment might improve capillary blood flow and prevent organ failure in these patients.
The failure of levosimendan to reduce the severity of organ failure in the recent trial does not disprove the theory that altered cellular microcirculatory flow drives organ dysfunction in sepsis. The fact that no major between-group differences in haemodynamics or oxygen delivery were reported does, however, reduce the likelihood that levosimendan substantially impacts microcirculatory flow. Findings from this study and others suggest that improving global haemodynamics is unlikely to improve cellular oxygen metabolism. Three large randomized controlled trials previously showed no difference in any outcome measure between patients with sepsis who received conventional therapy and those who received therapy that aimed to maximize oxygen delivery (that is, increased fluid loading, blood administration and dobutamine administration, if necessary) 4 . By contrast, a remarkable study in which patients with septic shock were treated with the β-blocker esmolol to slow heart rate to between 80-94 bpm during the first 96 h of their stay in the intensive care unit (ICU) showed a highly significant mortality benefit in the intervention group In this study, levosimendan treatment did not lead to reduced severity of organ dysfunction or lower mortality in comparison to standard care 2 . Importantly, no significant between-group differences were reported in cardiac index, central venous oxygen saturation, PaO 2 :FiO 2 ratio, serum creatinine or bilirubin levels (a marker of liver function). Patients in the levosimendan group received more noradrenaline and were less likely to be weaned from mechanical ventilation than those in the placebo group. No betweengroup differences were detected in any measure of renal function.
The negative result of this trial underscores a key issue that has long perplexed clinicians and sepsis researchers, namely what is the mechanism of multiple organ failure in sepsis? One of the main theories is that this organ failure results from impaired oxygen delivery at the cellular level owing to altered microcirculatory blood flow 3 (FIG. 1) . Although global oxygen delivery is typically increased in sepsis (once patients are adequately volume resuscitated), proponents of this theory suggest that many tissue capillary beds do not receive adequate oxygen supplies because of microvascular endothelial injury and the vasodilatory effects of various mediators that are released during sepsis 2, 3 . The end result is shunting of blood away from selected tissue beds and the development of a relative deficiency in oxygen delivery at the cellular level. Although levosimendan has multiple effects, the most (49.4% versus 80.5% in the control group, P <0.001) 5 . This therapy reduced oxygen delivery, but apparently not to a level that was detrimental to this population. Microcirculatory impairment with shunting and maldistribution of blood flow, therefore, seems unlikely to be central to the pathophysiology of sepsis-induced organ failure.
If abnormal global circulatory flow is not the driving force for sepsis-induced multiple organ dysfunction, what is responsible? A second evolving theory is that persistent inflammation, immunosuppression, and accelerated protein catabolism leads to loss of lean muscle mass, poor wound healing, and recurrent infections 6 (FIG. 1) . The end result of this constellation of events, which has been termed persistent inflammation, immunosuppression and catabolism syndrome (PICs), is multiple organ failure and death. Undoubtedly, localized inflammation at sites of infection, muscle wasting, impaired immunity, and delayed healing all occur in patients with sepsis. These adverse processes contribute to the high incidence of secondary hospital-acquired infections and frequent hospital readmissions in this population. It is difficult, however, to directly relate inflammation, immunosuppression and accelerated protein catabolism to organ dysfunction.
The absence of widespread cell injury on histopathologic examination of tissue from septic patients with severe organ dysfunction has led some investigators to propose a third theory -cell hibernation rather than cell death is responsible for organ dysfunction in sepsis (FIG. 1) . To investigate the role of cell death, our group performed rapid bedside autopsies in patients who died of sepsis 7, 8 . We found a remarkable paucity of cell death in heart, kidney and liver tissue. Cardiomyocyte death was rare, occurring in <1-2% of cells. Renal tubular injury was common but focal. Most renal tubular cells appeared normal and the degree of renal tubular injury and tubular cell death did not account for the severity of renal failure and requirement for dialysis. Hepatocyte necrosis and apoptosis was present in seven of 20 patients but was predominantly located in proximity to the hepatic central vein, a region vulnerable to low flow states. The lack of widespread necrotic or apoptotic cell death in these major organs, coupled with laboratory evidence of organ failure, is consistent with cell stunning or hibernation as an aetiology of organ impairment.
If severe cell injury and cell death does not occur in the major organs of septic patients, why do these patients die? Among patients with sepsis in the ICU, most deaths are not the direct result of organ failure. Studies show that cardiac output is maintained until shortly before death. Renal failure occurs but dialysis prevents fatal metabolic derangements, and liver dysfunction rarely progresses to fulminant hepatic failure. Most deaths occur when the patient's family and physicians decide that the prognosis for meaningful recovery is poor and ongoing efforts are not consistent with patient goals, leading to a shift from aggressive support to comfort measures only.
The take-home message is that clinicians caring for patients with sepsis should follow the fundamentals outlined in the Surviving Sepsis Campaign, including adequate volume resuscitation based upon clinical and laboratory findings, such as urine output, lactate levels and central venous oxygen saturation. Moreover, the sepsis community needs to shift attention to potential new approaches. In oncology, immunotherapy has led to a paradigm shift in patient care, resulting in lengthy remissions and improved durable survival. Given the similarities of the immunologic defects in patients with cancer and those with sepsis, immunotherapy likely offers great promise for the treatment of sepsis 9, 10 and multiple clinical trials of immunoadjuvants are currently underway. Effective immunotherapy to restore host immunity might lead to control of the initial infection and prevent new secondary infections. An effective host immune response is the key to reducing organ failure in sepsis, and the lack of substantial cell death in the major organs of patients who have died of the disorder suggests that recovery is possible if infections can be controlled.
